Genitourinary Cancers

The panel discusses strategies for monitoring patients with non–muscle invasive bladder cancer and the potential role of biomarkers.

Expert oncologists discuss the challenges and considerations in choosing second-line therapy for a patient with metastatic renal cell carcinoma (RCC) in a case-based context.

Stefan Maksimovic, MD, discusses the preclinical investigation of innovative tissue engineering with optical windows, state-of-the-art fluorescence reporter technology, and intravital multiphoton microscopy in mouse models with clear cell renal cell carcinoma.

Final outcomes from the phase 1b/2 Study 111/KEYNOTE-146 trial, evaluating treatment with lenvatinib and pembrolizumab in patients with advanced renal cell carcinoma, has sparked interest in the use of this combination.

Jose A. Karam, MD, FACS, discusses key takeaways from the 2023 International Kidney Cancer Symposium.

Eric Jonasch, MD, discusses the evolution of belzutifan in cancer care, highlighting the agent’s potential for the treatment of patients with renal cell carcinoma.

Ulka Nitin Vaishampayan, MBBS, discusses the rationale for conducting the phase 3 SWOG 1931 trial in patients with advanced renal cell carcinoma.

Expert perspectives on treatment options available for patients with bladder cancer and the role of trimodal therapy.

A panel of experts on bladder cancer provide an overview of the stratification, natural history, and treatment of bladder cancer.

Michael Hurwitz, MD, PhD, discusses the ongoing investigation into the use of CAR T-cell therapies in patients with solid tumors, such as kidney cancers.

Arpita Desai, MD, discusses the impact that the findings from the phase 3 CONTACT-03 trial had in patients with metastatic renal cell carcinoma.

Qian (Janie) Qin, MD, discusses upcoming areas of interest in the renal cell carcinoma armamentarium.

Renowned oncologists discuss critical factors influencing their decisions for frontline therapy in metastatic renal cell carcinoma (RCC), including risk assessment, sites of metastasis, performance status, and treatment goals.

A comprehensive discussion on VEGF-TKI-based combinations and immune checkpoint inhibitor combinations in the treatment of renal cell carcinoma, featuring key clinical trial results and treatment strategies.

Manojkumar Bupathi, MD, MS, discusses treating patients with renal cell carcinoma in community vs academic settings.

Pedro Barata, MD, MSc, discusses the biggest clinical trial updates to emerge for the treatment of patients with advanced renal cell carcinoma from the 2023 International Kidney Cancer Symposium.

Benjamin Garmezy, MD, discusses the treatment of patients with cancer in the community care setting, highlighting the need to include those from this population in enrollment to clinical trials.

Tian Zhang, MD, MHS, discusses the evolution of the use of belzutifan in renal cell carcinoma, highlighting which key oncologists have been involved in this research.

Alan Tan, MD, discusses the ongoing potential utility of circulating tumor DNA in patients with renal cell carcinoma and highlights how this approach is being used in his own practice.

Expert panelists review the management of non-clear cell histology in renal cell carcinoma, exploring treatment options, clinical trials, and the potential role of immune checkpoint inhibitors.

Brett L. Ecker, MD, discusses the evaluation of the microbiome in pancreatic cancer, highlighting remaining questions and future steps for research.

Interrupting combination treatment with axitinib and avelumab and switching to avelumab maintenance after a response at 36 weeks led to a decrease in treatment-related toxicities and delayed tumor progression in previously untreated patients with metastatic clear cell renal cell carcinoma.

Volrustomig demonstrated efficacy when used as frontline treatment in patients with clear cell renal cell carcinoma with a toxicity profile that is consistent with dual checkpoint inhibition.

Key opinion leaders discuss the use of brain MRI and bone assessment in the staging and monitoring of patients with renal cell carcinoma.

Renowned oncologists discuss the case of a 75-year-old man with advanced renal cell carcinoma, providing insights into evaluation and frontline therapy choices.

Although not immediately practice changing, CAR T-cell therapy has the potential to become a standard of care for patients with advanced renal cell carcinoma following progression on checkpoint inhibitors and VEGF inhibitors.

Additional research exploring the association between clonal hematopoiesis and cardiovascular health could help improve outcomes for patients with kidney cancer and identify those at higher risk for experiencing cardiac events.

Further understanding of the cancer immunity cycle could drive the development of novel immune therapies for patients with renal cell carcinoma.

Decisions regarding the intensification or de-escalation of treatment, particularly with immunotherapy and TKIs, for patients with renal cell carcinoma could be aided by circulating tumor DNA.

Brian H. Ramnaraign, MD, discusses findings from a single-institution review of the incidence of immunotherapy-related toxicities in older patients with kidney cancer.